API Quick Links: http://en.hichipharm.com/

+86-152-0110-8103 yanglm@beilupharma.com

EN

EN
jp
fr
de
es
ru
pt
ar

- English
- 日本語
- français
- Deutsch
- Español
- русский
- português
- العربية

Iohexol Injection of Beilu Pharmaceutical Receives MA in the EU

2025/04/11

/uploads/image/2025/04/11/beilu-20250411.jpg

Recently, Beijing Beilu Pharmaceutical Co., Ltd. received the "Marketing Authorization" (MA) issued by the Netherlands Medicines Evaluation Board (MEB) in accordance with the relevant regulations of the European Medicines Agency.

This indicates that the Iohexol Injection has obtained the relevant drug review and technical approvals from EU member states and is now eligible for sale in EU-approved countries. This will help Beilu Pharmaceutical further promote the expansion of its overseas market and enhance the international market competitiveness of its contrast agent products, which is expected to have a positive impact on the company's operations in the future.

Related Products

Gadopentetate Monomeglumine

Gadopentetate Monomeglumine

Iodixanol Injection

Iodixanol Injection

Related News

What is the Contrast Material? How Does It Work?
July 5, 2022Ⅰ. What is the contrast material?Contrastive material is used to improve the contrast of the images produced by X-rays, computed tomography (CT), magnetic resonance (MR) imaging, and ultrasound, allo...view
To Understand the Development of Iodinated Contrast Agents
May 13, 2021For the purpose of medical imaging, a certain substance is introduced into the human body to change the image contrast of the body's local tissues.view
Beilu Pharma Established a Wholly-owned R&D Subsidiary
September 7, 2022Taking the "Top 100 Chinese Pharmaceutical Enterprises" as the medium and long-term goal, Beilu Pharma has decided to choose not only the Contrast Agent field, Central Nervous System (Propri...view
Beilu Pharmaceutical's Repaglinide Tablets Receive Generic Drug Bioequivalence Assessment
June 6, 2023Recently, Beilu Pharmaceutical received the "Drug Supplement Application Approval Notice" (Notice No.: 2023B02662) for repaglinide tablets issued by the National Medical Products Administrat...view
Beilu Pharmaceutical Officially Acquires Tianyuan Pharmaceutical, Continues to Advance the Strategic Layout of Traditional Chinese Medicine
April 18, 2024In recent days, Beilu Pharmaceutical has disclosed the "Announcement on the Acquisition of 80% Equity Interest in Chengde Tianyuan Pharmaceutical Co., Ltd.".The Acquisition Is Progressing Sm...view
Beilu Pharmaceutical has Won the '2022 China Top 500 Corporate Philanthropy' Award!
February 24, 2023Recently, the "Wealth and Responsibility - Values of Enterprises" 2022 China Top 500 Charity List Conference was held in Chongqing. Since its inclusion in 2021, Beilu Pharmaceutical has been...view

Call us on:
+86-152-0110-8103
Email Us:
yanglm@beilupharma.com
No.3 Shuiyuan West Road, Miyun District, Beijing, China

Sitemap | Privacy Policy
Copyright © Beijing Beilu Pharmaceutical Co., Ltd. All Rights Reserved.

+86-152-0110-8103